![Glenn Larsen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Glenn Larsen
Amministratore Delegato presso
Aquinnah Pharmaceuticals, Inc.
Patrimonio netto: 730 249 $ in data 31/05/2026
Profilo
Glenn R.
Larsen is the founder of Aquinnah Pharmaceuticals, Inc., founded in 2014, serving as Chairman, President & Chief Executive Officer.
Dr. Larsen was the founder of 180 Therapeutics LP, founded in 2013, serving as Chairman from 2013 to 2020.
Former jobs include Senior Director at Genetics Institute LLC from 2003 to 2010; COO, Director & Executive VP-Development at Hydra Biosciences, Inc. from 2003 to 2010; Independent Director at Anika Therapeutics, Inc. from 2015 to 2026; Vice President at Wyeth Pharmaceuticals LLC; and CSO, Executive VP-Research & Development at SpringLeaf Therapeutics, Inc. from 2012 to 2013.
Education includes a doctorate from Stony Brook University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 21/04/2026 | 50.258 ( 0,38% ) | 730 249 $ | 31/05/2026 |
Posizioni attive di Glenn Larsen
| Società | Posizione | Inizio |
|---|---|---|
Aquinnah Pharmaceuticals, Inc.
 Aquinnah Pharmaceuticals, Inc. BiotechnologyHealth Technology Engages in research and development to modulate neurodegenerative stress granules | Amministratore Delegato | 01/02/2014 |
Precedenti posizioni note di Glenn Larsen
| Società | Posizione | Fine |
|---|---|---|
| ANIKA THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 18/06/2026 |
180 Therapeutics LP
 180 Therapeutics LP Pharmaceuticals: MajorHealth Technology Engages in development of biological therapies for the treatment of fibrosis | Fondatore | 01/01/2020 |
SpringLeaf Therapeutics, Inc.
 SpringLeaf Therapeutics, Inc. Drugstore ChainsRetail Trade Develops various drug delivery technologies | Direttore Tecnico/Scientifico/R&S | 01/01/2013 |
Hydra Biosciences, Inc.
 Hydra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops molecular regeneration medicines to treat pain, inflammation, anxiety and other diseases | Direttore Tecnico/Scientifico/R&S | 01/01/2010 |
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Direttore/Membro del Consiglio | 01/01/2010 |
Formazione di Glenn Larsen
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
29
Relazioni di 1° grado
8
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 8 |
|---|---|
Genetics Institute LLC
Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
Anika Therapeutics, Inc.
 Anika Therapeutics, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair | Health Technology |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets infant pharmaceutical products | Health Technology |
SpringLeaf Therapeutics, Inc.
SpringLeaf Therapeutics, Inc. Drugstore ChainsRetail Trade Develops various drug delivery technologies | Retail Trade |
Stony Brook University
 Stony Brook University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hydra Biosciences, Inc.
Hydra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Develops molecular regeneration medicines to treat pain, inflammation, anxiety and other diseases | Health Technology |
Aquinnah Pharmaceuticals, Inc.
Aquinnah Pharmaceuticals, Inc. BiotechnologyHealth Technology Engages in research and development to modulate neurodegenerative stress granules | Health Technology |
180 Therapeutics LP
180 Therapeutics LP Pharmaceuticals: MajorHealth Technology Engages in development of biological therapies for the treatment of fibrosis | Health Technology |
